What is a stock summary page? Click here for an overview.
Business Description
Werewolf Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US95075A1079
Compare
Compare
Traded in other countries / regions
HOWL.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2021-04-30Description
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.99 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | -0.58 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.95 | |||||
| Beneish M-Score | -6.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.6 | |||||
| 3-Year EPS without NRI Growth Rate | 47.1 | |||||
| 3-Year FCF Growth Rate | 18.2 | |||||
| 3-Year Book Growth Rate | -33.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 83.44 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.86 | |||||
| 9-Day RSI | 20.18 | |||||
| 14-Day RSI | 23.87 | |||||
| 3-1 Month Momentum % | -32.14 | |||||
| 6-1 Month Momentum % | -43.28 | |||||
| 12-1 Month Momentum % | -81.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.45 | |||||
| Quick Ratio | 7.45 | |||||
| Cash Ratio | 7.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18 | |||||
| Shareholder Yield % | -32.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3904.19 | |||||
| Net Margin % | -3740.85 | |||||
| FCF Margin % | -2994.27 | |||||
| ROE % | -71.12 | |||||
| ROA % | -45.61 | |||||
| ROIC % | -237.15 | |||||
| 3-Year ROIIC % | 972.17 | |||||
| ROC (Joel Greenblatt) % | -487.18 | |||||
| ROCE % | -47.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.97 | |||||
| PB Ratio | 0.46 | |||||
| Price-to-Tangible-Book | 0.46 | |||||
| EV-to-EBIT | 0.58 | |||||
| EV-to-EBITDA | 0.59 | |||||
| EV-to-Revenue | -20.19 | |||||
| EV-to-Forward-Revenue | 0.22 | |||||
| EV-to-FCF | 0.58 | |||||
| Price-to-GF-Value | 2.41 | |||||
| Price-to-Net-Current-Asset-Value | 0.56 | |||||
| Price-to-Net-Cash | 0.58 | |||||
| Earnings Yield (Greenblatt) % | 172.41 | |||||
| FCF Yield % | -168.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HOWL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Werewolf Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.885 | ||
| EPS (TTM) ($) | -1.66 | ||
| Beta | 0.51 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.3 | ||
| Volatility % | 60.95 | ||
| 14-Day RSI | 23.87 | ||
| 14-Day ATR ($) | 0.091758 | ||
| 20-Day SMA ($) | 1.095635 | ||
| 12-1 Month Momentum % | -81.06 | ||
| 52-Week Range ($) | 0.7354 - 6.89 | ||
| Shares Outstanding (Mil) | 44.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Werewolf Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Werewolf Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Werewolf Therapeutics Inc Frequently Asked Questions
What is Werewolf Therapeutics Inc(HOWL)'s stock price today?
The current price of HOWL is $0.75. The 52 week high of HOWL is $6.89 and 52 week low is $0.74.
When is next earnings date of Werewolf Therapeutics Inc(HOWL)?
The next earnings date of Werewolf Therapeutics Inc(HOWL) is 2025-05-02 Est..
Does Werewolf Therapeutics Inc(HOWL) pay dividends? If so, how much?
Werewolf Therapeutics Inc(HOWL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers